Condition: Recurrent Childhood Acute Myeloid Leukemia · Recurrent Childhood Acute Lymphoblastic Leukemia · Recurrent Childhood Large Cell Lymphoma · Sponsor: Florida International University
Functional precision medicine (FPM) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug sensitivity testing (DST) and genomic profiling to determine the optimal individualized therapy for cancer patients. In this study, we will enroll relapsed or refractory pediatric cancer patients with tissue available for DST and genomic profiling from the South Florida area, which is 69% Hispanic and 18% Black. Tumor cells collected from tissue taken during routine biopsy or surgery will be tested.
This description comes directly from the study's public registry record.
Diana Azzam, PhD · 305-348-9043 · fpmlab@fiu.edu
Lillian Garvin · 800-533-1792 · exvivotrial@nicklaushealth.org
Always discuss trial participation with your own doctor first.
| Nicklaus Children's Hospital | Miami, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05857969